For example, IL-17 is a well-known target for PSO treatment (50) and has been explored in therapy for lupus (51, 52) and AD (53); however, we did not observe consistent up-regulation of the IL-17 complex signature among the lesional manifestations of DLE, AD, and SSc, suggesting that IL-17–neutralizing therapy may be best suited for lesional PSO alone. The gene discussed is IL17A; the disease is discoid lupus erythematosus.